Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30106

Type
Article
Copyright
Restricted access
Embargo date
2028-08-30
Collections
Share

Statistics
Metadata
Show full item record

WEEK 48 ANALYSIS OF ONCE-DAILY VS. TWICE-DAILY DARUNAVIR/RITONAVIR IN TREATMENT-EXPERIENCED HIV-1-INFECTED PATIENTS
Cahn, Pedro et al. | Date Issued: 2011
Author
Cahn, Pedro
Fourie, Jan
Grinsztejn, Beatriz
Hodder, Sally
Molina, Jean-Michel
Ruxrungtham, Kiat
Workman, Cassy
Van De Casteele, Tom
De Doncker, Piet
Lathouwers, Erkki
Tomaka, Frank
Affilliation
Fundación Huesped. Buenos Aires, Argentina.
Dr Jan Fourie Medical Practice. Dundee, KwaZulu Natal, South Africa.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of Medicine and Dentistry of New Jersey. Newark, New Jersey, USA.
Hôpital St Louis. Paris, France.
Chulalongkorn University. Thai Red Cross AIDS Research Centre and Faculty of Medicine. Bangkok, Thailand.
AIDS Research Initiative. Darlinghurst, Australia.
Tibotec BVBA. Beerse, Belgium.
Tibotec BVBA. Beerse, Belgium.
Tibotec BVBA. Beerse, Belgium.
Tibotec Inc. Titusville, New Jersey, USA.
Abstract
ODIN (Once-daily Darunavir In treatment-experieNced patients) was a phase III, 48-week, open-label study comparing once-daily vs. twice-daily darunavir/ritonavir (DRV/r) in treatment-experienced patients with no DRV resistance-associated mutations (RAMs) at screening.
Keywords
Darunavir
Efficacy
HIV
Once-daily
Safety
Treatment-experienced
Twice-daily
 
Citation
CAHN, Pedro. et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS, v. 25, p. 929–939, 2011.
DOI
10.1097/QAD.0b013e328345ee95
ISSN
0269-9370